James C D, Carlbom E, Dumanski J P, Hansen M, Nordenskjold M, Collins V P, Cavenee W K
Ludwig Institute for Cancer Research, Montreal, Canada.
Cancer Res. 1988 Oct 1;48(19):5546-51.
Comparison of constitutional and tumor genotypes at chromosomal loci defined by restriction fragment length alleles has proven useful in determining the genomic position and tissue specificity of recessive mutations that predispose to cancer (Hansen, M.F., and Cavenee, W.K. Cancer Res., 47:5518-5527, 1987). Here we have applied this approach to 53 unrelated patients with glial tumors of varying histological malignancy grade. Loss of constitutional heterozygosity for loci on chromosome 10 was observed in 28 of 29 tumors histologically classified as glioblastoma (malignancy grade IV) whereas no similar losses were observed in any of 22 gliomas of lower malignancy grade. Examination of restriction fragment length alleles on other chromosomes revealed that loss of sequences on chromosomes 13, 17, or 22 had occurred at nonrandom frequencies and in at least one instance of each malignancy grade of adult glioma. The tumors in which loss of constitutional heterozygosity was observed were composed of one or a mixture of glial cell subtypes displaying astrocytic, oligodendrocytic, and/or ependymal differentiation. These results demonstrate a close association of the loss of chromosome 10 sequences with the most malignant histological stage of glioma and that glioblastoma arises as the clonal expansion of an earlier staged precursor. Furthermore they suggest that glioblastoma is a common phenotypic and malignancy terminus for glial tumors of various cellular subtypes which is reached through a common molecular pathway. This approach which involves the identification of malignancy stage specific somatic losses of heterozygosity provides a genotypic, rather than phenotypic, analysis of tumor progression.
通过限制性片段长度等位基因定义的染色体位点上的构成基因型与肿瘤基因型的比较,已被证明有助于确定易患癌症的隐性突变的基因组位置和组织特异性(Hansen, M.F., and Cavenee, W.K. 《癌症研究》,47:5518 - 5527, 1987)。在此,我们将这种方法应用于53例组织学恶性程度不同的胶质肿瘤的非相关患者。在组织学分类为胶质母细胞瘤(恶性程度IV级)的29个肿瘤中的28个中观察到10号染色体上位点的构成杂合性缺失,而在22个低恶性程度的神经胶质瘤中均未观察到类似的缺失。对其他染色体上的限制性片段长度等位基因的检测显示,13、17或22号染色体上序列的缺失以非随机频率发生,并且在成人胶质瘤的每个恶性程度中至少有一个实例。观察到构成杂合性缺失的肿瘤由显示星形细胞、少突胶质细胞和/或室管膜分化的一种或多种胶质细胞亚型组成。这些结果表明10号染色体序列的缺失与胶质瘤最恶性的组织学阶段密切相关,并且胶质母细胞瘤是较早阶段前体的克隆性扩增产生的。此外,它们表明胶质母细胞瘤是各种细胞亚型的胶质肿瘤通过共同分子途径达到的常见表型和恶性终点。这种涉及鉴定恶性阶段特异性杂合性体细胞缺失的方法提供了肿瘤进展的基因型而非表型分析。